Filter
7
Filtered Results: 7
Text search:
Infectious
Diseases
Data
Observatory
IDDO
Featured
Recommendations
1
Language
Document type
Studies & Reports
4
Fact sheets
2
Guidelines
1
Countries / Regions
Global
2
Latin America and the Carribbean
1
Authors & Publishers
Publication Years
Category
Leishmaniasis
2
Disease Prevention & Control
2
Chagas
1
Studies & Reports
1
Pharmacy & Technologies
1
Toolboxes
Studies & Reports
2
Clinical Guidelines
1
Falsified & Substandard
1
Quality Assurance
1
Chagas
1
Leishmaniasis
1
Capacity Building & Resources
1
Studies & Reports
1
Overview, Studies & Reports
1
In September, 2018, the first international Medicine Quality and Public Health Conference was held at Oxford University, UK, to discuss opportunities and solutions to ensure that all people have access to affordable and quality-assured medical products. Delegates developed the short Oxford Statement...
A living WHO guideline on drugs for covid-19
recommended
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...
PLoS Neglected Tropical diseases August 16, 2021 https://doi.org/10.1371/journal.pntd.0009697
Chagas disease, also known as American trypanosomiasis, is a neglected tropical disease transmitted by triatomine insects, first identified in 1909. Chagas disease affects approximately 6–7 million peop...
The Chagas disease data platform is founded upon a collaborative framework that aims to bring together partners including individual researchers in Chagas endemic regions, leading global research institutions, policy specialists and funders from across the globe. The theme is coordinated by a team b...
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses to address the many outstanding resea...
Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ...
The results of a large-scale systematic review and meta-analysis have published in PLOS Neglected Tropical Diseases. This research aimed to collate all reported serious adverse events (SAE) in visceral leishmaniasis (VL) clinical trials and quantify the incidence of mortality during the first 30 day...
